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proteins (SREBPs) in the development of fat redistribution
and adipocyte transformation associated with unine-
phrectomy-induced chronic renal impairment.1 SREBPs
are membrane-bound transcription factors that regulate
multiple genes involved in cholesterol biosynthesis and
uptake.2 In our ongoing studies, we aim to define the
correlations between SREBPs and fat dysfunction con-
comitant with the course of chronic kidney disease in
uninephrectomized rats. Chmielewski et al. have demon-
strated an increased gene expression and protein abun-
dance of SREBPs in white adipose tissue3 and livers4 of 5/6
nephrectomized rats. Although these cross-sectional re-
sults complement our findings of fat dysfunction in
uninephrectomized rats,1 one has to be cautious in
interpreting data from different nephrectomized experi-
mental models. Renal failure model set up by 2/3, 5/6, or
7/8 nephrectomy might be different from the chronic
kidney impairment induced by uninephrectomy in our
study.1 For example, our study demonstrated that the
protein abundance of HMG-CoA reductase in the liver was
similar among the three groups of rats with different lipid
profiles.1 As stated in our paper,1 ‘nephrectomy is a severe
procedure that produces a myriad of effects on many
systems, including the renin–angiotensin–aldosterone sys-
tems and the endocrine organs’. Indeed, the uninephrecto-
mized rats also showed pancreatic b-cell deficit, insulin
deficiency, and glucose intolerance.5 All these data
demonstrate that the kidney is one of the most important
homeostatic organs.
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To the Editor: A recent article demonstrated that 8-week
paricalcitol treatment of 5/6 nephrectomized rats suppressed
expression of several genes of the renin-angiotensin system
(RAS) in the kidney at the mRNA level.1 We recently
performed a similar study,2 and have now determined
the RAS components from the kidneys with very different
results.
In our experiment, rats were put on a 12-week paricalcitol
(200 ng/kg) treatment period 15 weeks after 5/6 nephrectomy
(NX). After 27 weeks of renal insufficiency, the mRNA values
of almost all RAS components and connective tissue growth
factor were different from sham-operated rats. However, no
suppression of RAS genes between untreated and paricalcitol-
treated NX rats was observed at the mRNA level (Table 1). In
the study by Freundlich et al.,1 the NX rats were put on
paricalcitol (100 or 300 ng/kg) already 4 days after surgery.
The subtotal NX produces a shock that undoubtedly alters
gene expression in the remnant kidney, and it seems likely
that these processes have not yet stabilized in 4 days. In our
Table 1 | No differences in RAS components between untreated and paricalcitol-treated NX rats (200 ng/kg thrice weekly)
Sham (n=12) NX (n=7) NX+Paricalcitol (n=8)
Kidney mRNA using RT–PCR
AT1a receptor ( 104/ng total RNA) 0.99±0.04 0.83±0.08* 0.80±0.05*
AT2 receptor ( 102/ng total RNA) 0.76±0.15 0.32±0.06* 0.19±0.03*
AT4 receptor ( 103/ng total RNA) 2.99±0.21 3.76±0.28* 3.90±0.24*
Renin receptor ( 104/ng total RNA) 2.31±0.15 1.77±0.11* 1.74±0.08*
MAS oncogene ( 102/ng total RNA) 4.80±0.34 4.92±0.48 4.77±0.41
ACE ( 104/ng total RNA) 0.98±0.68 1.72±0.21* 2.06±0.20*
ACE2 ( 104/ng total RNA) 1.10±0.08 0.65±0.14* 0.49±0.09*
CTGF ( 104/ng total RNA) 1.74±0.11 2.76±0.49* 2.84±0.19*
Plasma renin activity (ng/ml/h) 24.3±3.0 1.7±1.0* 1.4±0.7*
ACE, angiotensin-converting enzyme; CTGF, connective tissue growth factor; NX, 5/6 nephrectomy; RT–PCR, reverse transcription–polymerase chain reaction.
5/6 nephrectomy at the age of 8 weeks (study week 0), disease progression period 0–15 weeks, treatment period 15–27 weeks (12 weeks). Mean±s.e.m., *Po0.05 compared
with the sham group.
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experiment, the treatment started 15 weeks after surgery in
established chronic renal insufficiency. This situation more
resembles the clinical renal disease, and may explain the
differences in the observed results.
We conclude that paricalcitol treatment does not always
suppress RAS components in the kidney, and suggest that the
observed effects of paricalcitol on RAS gene expression in
remnant kidneys may depend on the timing of the treatment.
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The comments by Karavalakis et al. refer to their
experiments in which paricalcitol administration was
delayed for 15 weeks following 5/6 nephrectomy and
maintained for 12 weeks.1 In the supplementary table
provided in their above letter, reverse transcription–PCR
determinations of various renin-angiotensin system (RAS)
components were not modified by paricalcitol treatment
and they suggest that the suppression of the RAS
components in our experiments is related to a nonspecific
postsurgical reduction of gene expression and/or the
timing of the therapeutic intervention.
To be noted, in their work reverse transcription–PCR
determinations of several RAS components display incon-
sistent directional variability with either up- or down-
regulated levels in kidney tissues of both treated and
untreated nephrectomized animals compared to sham.
Their findings of simultaneous downregulation of AT1R
and AT2R as well as that of the renin receptor in the
remnant kidney are in contrast with the results of others2,3
as well as ours.4 If what they observed is confirmed, then
the question is whether the ability of paricalcitol to
suppress an already downregulated genetic system in
kidneys with advanced chronic kidney disease is detect-
able. Unfortunately, neither renin nor additional RAS
genes mRNA or their protein expressions are shown, and
no indication about effects of functional or histopatholo-
gical changes in the remnant kidney by the delayed
paricalcitol treatment is given.
It is not clear what the authors mean by the shock
produced by the nephrectomy and its effects on gene
expression, because this is a well established experimental
model employed to evaluate the effects of early therapeutic
intervention on multiple molecular markers linked to
progressive chronic renal insufficiency.3 Furthermore, in
our own experiments,4 there was not a universal suppres-
sion of the renal mRNAs of the RAS but a specific
reduction in only some components, which argues against
a postsurgical nonspecific inhibition.
We agree with Karavalakis et al. that as we started
paricalcitol 4 days after nephrectomy and they started 15
weeks later, the experiments are not strictly comparable
and the timing of the therapeutic intervention could be the
reason for the differences between our results and theirs.
Unpublished observations in our laboratories indicate that
delaying paricalcitol treatment for 8 weeks after nephrect-
omy essentially abrogates the functional and histological
improvement of vitamin D analogues in the renal ablation
model.
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